famotidine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| histamine-H2-receptor antagonists, cimetidine derivatives | 1129 | 76824-35-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. Computer-aided, structure-based, virtual screening of libraries of compounds against SARS-CoV-2 proteins suggested potential for famotidine to interact with viral proteases in-volved in coronavirus replication. HOWEVER, there is no clinical trial evidence supporting efficacy or safety for treatment of COVID-19.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | mg | O |
| 40 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 67 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.98 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 42 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.80 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 15, 1986 | FDA | VALEANT PHARMS NORTH |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 287.13 | 9.21 | 703 | 105122 | 677135 | 45903102 |
| Rheumatoid arthritis | 224.84 | 9.21 | 133 | 105692 | 240082 | 46340155 |
| Contraindicated product administered | 136.78 | 9.21 | 12 | 105813 | 79935 | 46500302 |
| Drug intolerance | 131.10 | 9.21 | 86 | 105739 | 146963 | 46433274 |
| Synovitis | 116.92 | 9.21 | 5 | 105820 | 61070 | 46519167 |
| Hepatic function abnormal | 110.08 | 9.21 | 242 | 105583 | 34179 | 46546058 |
| Treatment failure | 109.73 | 9.21 | 37 | 105788 | 93050 | 46487187 |
| Gastrooesophageal reflux disease | 102.66 | 9.21 | 386 | 105439 | 73958 | 46506279 |
| Chronic kidney disease | 99.02 | 9.21 | 258 | 105567 | 40613 | 46539624 |
| Joint swelling | 94.32 | 9.21 | 144 | 105681 | 165929 | 46414308 |
| Pneumonia aspiration | 91.92 | 9.21 | 214 | 105611 | 31391 | 46548846 |
| Drug abuse | 88.41 | 9.21 | 18 | 105807 | 63390 | 46516847 |
| Toxicity to various agents | 86.37 | 9.21 | 223 | 105602 | 211543 | 46368694 |
| White blood cell count decreased | 81.31 | 9.21 | 483 | 105342 | 111748 | 46468489 |
| Platelet count decreased | 80.68 | 9.21 | 443 | 105382 | 99581 | 46480656 |
| Therapeutic product effect decreased | 70.00 | 9.21 | 51 | 105774 | 82550 | 46497687 |
| Disseminated intravascular coagulation | 58.93 | 9.21 | 132 | 105693 | 18873 | 46561364 |
| Off label use | 57.14 | 9.21 | 568 | 105257 | 379273 | 46200964 |
| Arthropathy | 54.53 | 9.21 | 67 | 105758 | 84633 | 46495604 |
| Completed suicide | 51.14 | 9.21 | 165 | 105660 | 145755 | 46434482 |
| Cholecystitis chronic | 50.90 | 9.21 | 88 | 105737 | 10411 | 46569826 |
| Aspartate aminotransferase increased | 50.87 | 9.21 | 329 | 105496 | 78371 | 46501866 |
| Systemic lupus erythematosus | 50.50 | 9.21 | 44 | 105781 | 65136 | 46515101 |
| Hand deformity | 49.92 | 9.21 | 9 | 105816 | 34565 | 46545672 |
| Neutrophil count decreased | 48.37 | 9.21 | 211 | 105614 | 43215 | 46537022 |
| Maternal exposure during pregnancy | 47.34 | 9.21 | 101 | 105724 | 102448 | 46477789 |
| Arthralgia | 47.29 | 9.21 | 564 | 105261 | 364039 | 46216198 |
| Liver disorder | 46.98 | 9.21 | 188 | 105637 | 37058 | 46543179 |
| Drug hypersensitivity | 45.79 | 9.21 | 344 | 105481 | 243481 | 46336756 |
| Blood lactate dehydrogenase increased | 44.20 | 9.21 | 124 | 105701 | 20376 | 46559861 |
| Lower respiratory tract infection | 44.13 | 9.21 | 36 | 105789 | 55053 | 46525184 |
| Hepatocellular injury | 44.13 | 9.21 | 7 | 105818 | 29515 | 46550722 |
| Therapeutic product effect incomplete | 43.15 | 9.21 | 69 | 105756 | 78084 | 46502153 |
| Glossodynia | 40.81 | 9.21 | 25 | 105800 | 44348 | 46535889 |
| Dehydration | 39.92 | 9.21 | 544 | 105281 | 158996 | 46421241 |
| General physical health deterioration | 39.11 | 9.21 | 133 | 105692 | 115636 | 46464601 |
| Alanine aminotransferase increased | 39.11 | 9.21 | 338 | 105487 | 88113 | 46492124 |
| Interstitial lung disease | 36.38 | 9.21 | 228 | 105597 | 53721 | 46526516 |
| Angioedema | 35.64 | 9.21 | 180 | 105645 | 39162 | 46541075 |
| Musculoskeletal stiffness | 35.59 | 9.21 | 109 | 105716 | 97884 | 46482353 |
| Alopecia | 34.47 | 9.21 | 221 | 105604 | 162193 | 46418044 |
| Torsade de pointes | 33.92 | 9.21 | 81 | 105744 | 12073 | 46568164 |
| Butterfly rash | 33.11 | 9.21 | 23 | 105802 | 951 | 46579286 |
| Enterocolitis | 32.96 | 9.21 | 54 | 105771 | 6114 | 46574123 |
| Upper respiratory tract inflammation | 32.88 | 9.21 | 36 | 105789 | 2759 | 46577478 |
| Flushing | 31.27 | 9.21 | 252 | 105573 | 64362 | 46515875 |
| Overdose | 29.36 | 9.21 | 125 | 105700 | 101854 | 46478383 |
| Cerebral infarction | 27.92 | 9.21 | 116 | 105709 | 23250 | 46556987 |
| Exposure during pregnancy | 26.83 | 9.21 | 140 | 105685 | 108072 | 46472165 |
| End stage renal disease | 26.80 | 9.21 | 48 | 105777 | 5838 | 46574399 |
| Urticaria | 26.27 | 9.21 | 394 | 105431 | 117498 | 46462739 |
| Mental status changes | 25.69 | 9.21 | 161 | 105664 | 37927 | 46542310 |
| Product use issue | 25.45 | 9.21 | 119 | 105706 | 94525 | 46485712 |
| Foetal exposure during pregnancy | 24.74 | 9.21 | 20 | 105805 | 30727 | 46549510 |
| Gallbladder disorder | 23.42 | 9.21 | 90 | 105735 | 17408 | 46562829 |
| Injection site pain | 22.62 | 9.21 | 146 | 105679 | 107006 | 46473231 |
| Mobility decreased | 22.28 | 9.21 | 67 | 105758 | 60527 | 46519710 |
| Lip swelling | 22.16 | 9.21 | 115 | 105710 | 25280 | 46554957 |
| Drug resistance | 22.09 | 9.21 | 6 | 105819 | 17362 | 46562875 |
| Haemorrhage subcutaneous | 22.07 | 9.21 | 30 | 105795 | 2876 | 46577361 |
| Anaphylactic reaction | 21.94 | 9.21 | 200 | 105625 | 52912 | 46527325 |
| Hepatic enzyme increased | 21.30 | 9.21 | 104 | 105721 | 81683 | 46498554 |
| Red blood cell sedimentation rate increased | 20.90 | 9.21 | 13 | 105812 | 22876 | 46557361 |
| Renal injury | 20.85 | 9.21 | 58 | 105767 | 9483 | 46570754 |
| Knee arthroplasty | 20.84 | 9.21 | 14 | 105811 | 23651 | 46556586 |
| Chest discomfort | 20.62 | 9.21 | 303 | 105522 | 89966 | 46490271 |
| Pyrexia | 20.58 | 9.21 | 977 | 104848 | 347825 | 46232412 |
| Periorbital oedema | 20.34 | 9.21 | 39 | 105786 | 4996 | 46575241 |
| Drug eruption | 20.31 | 9.21 | 99 | 105726 | 21230 | 46559007 |
| Febrile neutropenia | 20.21 | 9.21 | 314 | 105511 | 94313 | 46485924 |
| Basophil count decreased | 20.07 | 9.21 | 8 | 105817 | 101 | 46580136 |
| Wound | 19.87 | 9.21 | 42 | 105783 | 42760 | 46537477 |
| Lactic acidosis | 19.61 | 9.21 | 29 | 105796 | 33880 | 46546357 |
| Lymphocyte stimulation test positive | 19.39 | 9.21 | 14 | 105811 | 616 | 46579621 |
| Drug interaction | 19.27 | 9.21 | 334 | 105491 | 202760 | 46377477 |
| Psoriatic arthropathy | 19.25 | 9.21 | 33 | 105792 | 36346 | 46543891 |
| Injection site reaction | 18.99 | 9.21 | 51 | 105774 | 47798 | 46532439 |
| Biliary dyskinesia | 18.64 | 9.21 | 27 | 105798 | 2746 | 46577491 |
| Device expulsion | 18.56 | 9.21 | 21 | 105804 | 27521 | 46552716 |
| Acquired haemophilia | 18.52 | 9.21 | 16 | 105809 | 915 | 46579322 |
| Constipation | 18.44 | 9.21 | 521 | 105304 | 173576 | 46406661 |
| Acute respiratory failure | 18.32 | 9.21 | 121 | 105704 | 29017 | 46551220 |
| Infective pulmonary exacerbation of cystic fibrosis | 18.25 | 9.21 | 60 | 105765 | 10747 | 46569490 |
| Cytokine release syndrome | 17.94 | 9.21 | 42 | 105783 | 6181 | 46574056 |
| Ventricular tachycardia | 17.80 | 9.21 | 81 | 105744 | 16886 | 46563351 |
| Pericarditis | 17.52 | 9.21 | 17 | 105808 | 23910 | 46556327 |
| Urinary tract infection | 17.30 | 9.21 | 636 | 105189 | 219630 | 46360607 |
| Pain | 17.19 | 9.21 | 895 | 104930 | 476053 | 46104184 |
| Loss of personal independence in daily activities | 17.13 | 9.21 | 69 | 105756 | 57114 | 46523123 |
| Arthritis | 16.49 | 9.21 | 105 | 105720 | 77211 | 46503026 |
| Dyspepsia | 16.09 | 9.21 | 231 | 105594 | 68241 | 46511996 |
| Rebound acid hypersecretion | 15.78 | 9.21 | 9 | 105816 | 262 | 46579975 |
| Blood alkaline phosphatase increased | 15.77 | 9.21 | 148 | 105677 | 39461 | 46540776 |
| Blood pressure fluctuation | 15.77 | 9.21 | 28 | 105797 | 30420 | 46549817 |
| Serotonin syndrome | 15.75 | 9.21 | 19 | 105806 | 24201 | 46556036 |
| Injection site bruising | 15.69 | 9.21 | 36 | 105789 | 35600 | 46544637 |
| Premature baby | 15.57 | 9.21 | 11 | 105814 | 18101 | 46562136 |
| Neuropathy peripheral | 15.55 | 9.21 | 291 | 105534 | 90602 | 46489635 |
| Cystitis noninfective | 15.51 | 9.21 | 14 | 105811 | 849 | 46579388 |
| Breast adenoma | 15.39 | 9.21 | 5 | 105820 | 33 | 46580204 |
| Cholinergic syndrome | 15.31 | 9.21 | 10 | 105815 | 373 | 46579864 |
| Lupus hepatitis | 15.27 | 9.21 | 5 | 105820 | 34 | 46580203 |
| Gallbladder injury | 14.97 | 9.21 | 17 | 105808 | 1357 | 46578880 |
| Intentional self-injury | 14.63 | 9.21 | 20 | 105805 | 24146 | 46556091 |
| Hypoxia | 14.29 | 9.21 | 180 | 105645 | 51658 | 46528579 |
| Respiratory alkalosis | 14.27 | 9.21 | 23 | 105802 | 2568 | 46577669 |
| Cytomegalovirus enterocolitis | 14.06 | 9.21 | 11 | 105814 | 547 | 46579690 |
| Allergy test positive | 14.04 | 9.21 | 9 | 105816 | 325 | 46579912 |
| Burkholderia test positive | 13.88 | 9.21 | 6 | 105819 | 94 | 46580143 |
| Hepatotoxicity | 13.87 | 9.21 | 22 | 105803 | 24987 | 46555250 |
| Disease progression | 13.83 | 9.21 | 287 | 105538 | 91013 | 46489224 |
| Chest pain | 13.81 | 9.21 | 509 | 105316 | 175815 | 46404422 |
| Cholecystitis acute | 13.78 | 9.21 | 43 | 105782 | 7495 | 46572742 |
| Psoriasis | 13.74 | 9.21 | 113 | 105712 | 78491 | 46501746 |
| Cholestasis | 13.68 | 9.21 | 25 | 105800 | 26868 | 46553369 |
| Therapeutic response decreased | 13.60 | 9.21 | 51 | 105774 | 43094 | 46537143 |
| Congenital neuropathy | 13.59 | 9.21 | 4 | 105821 | 18 | 46580219 |
| Granulocytopenia | 13.50 | 9.21 | 34 | 105791 | 5239 | 46574998 |
| Pyuria | 13.33 | 9.21 | 18 | 105807 | 1715 | 46578522 |
| Small intestinal obstruction | 13.27 | 9.21 | 72 | 105753 | 16100 | 46564137 |
| White blood cell count increased | 13.26 | 9.21 | 156 | 105669 | 44063 | 46536174 |
| Helicobacter infection | 13.25 | 9.21 | 5 | 105820 | 11731 | 46568506 |
| Hip arthroplasty | 13.11 | 9.21 | 13 | 105812 | 18099 | 46562138 |
| Pneumonia | 13.08 | 9.21 | 1006 | 104819 | 375314 | 46204923 |
| Throat irritation | 13.05 | 9.21 | 111 | 105714 | 28790 | 46551447 |
| Brain natriuretic peptide increased | 12.98 | 9.21 | 31 | 105794 | 4619 | 46575618 |
| Decreased appetite | 12.94 | 9.21 | 550 | 105275 | 193286 | 46386951 |
| Fibromyalgia | 12.92 | 9.21 | 41 | 105784 | 36422 | 46543815 |
| Victim of chemical submission | 12.73 | 9.21 | 8 | 105817 | 279 | 46579958 |
| Ill-defined disorder | 12.72 | 9.21 | 26 | 105799 | 26801 | 46553436 |
| Diarrhoea | 12.70 | 9.21 | 1451 | 104374 | 558151 | 46022086 |
| Full blood count decreased | 12.63 | 9.21 | 90 | 105735 | 22121 | 46558116 |
| Hypoparathyroidism | 12.54 | 9.21 | 11 | 105814 | 642 | 46579595 |
| Haematocrit decreased | 12.50 | 9.21 | 128 | 105697 | 34929 | 46545308 |
| Protein total decreased | 12.49 | 9.21 | 34 | 105791 | 5489 | 46574748 |
| Hospice care | 12.38 | 9.21 | 33 | 105792 | 5262 | 46574975 |
| Dizziness | 12.32 | 9.21 | 913 | 104912 | 339501 | 46240736 |
| Erythema multiforme | 12.25 | 9.21 | 49 | 105776 | 9655 | 46570582 |
| Tubulointerstitial nephritis | 12.24 | 9.21 | 66 | 105759 | 14722 | 46565515 |
| Asteatosis | 12.14 | 9.21 | 5 | 105820 | 69 | 46580168 |
| Gastritis | 12.01 | 9.21 | 125 | 105700 | 34253 | 46545984 |
| Hypoalbuminaemia | 11.88 | 9.21 | 50 | 105775 | 10077 | 46570160 |
| Ovarian cancer recurrent | 11.86 | 9.21 | 13 | 105812 | 998 | 46579239 |
| Osteoarthritis | 11.85 | 9.21 | 87 | 105738 | 61938 | 46518299 |
| Blood potassium decreased | 11.73 | 9.21 | 135 | 105690 | 37928 | 46542309 |
| Musculoskeletal pain | 11.72 | 9.21 | 102 | 105723 | 70026 | 46510211 |
| Rheumatoid nodule | 11.69 | 9.21 | 3 | 105822 | 9017 | 46571220 |
| Xanthogranuloma | 11.68 | 9.21 | 3 | 105822 | 7 | 46580230 |
| Anaphylactoid reaction | 11.67 | 9.21 | 25 | 105800 | 3466 | 46576771 |
| Hyperuricaemia | 11.64 | 9.21 | 30 | 105795 | 4687 | 46575550 |
| Neurological examination abnormal | 11.43 | 9.21 | 7 | 105818 | 233 | 46580004 |
| Cholelithiasis | 11.39 | 9.21 | 136 | 105689 | 38545 | 46541692 |
| Palmar erythema | 11.31 | 9.21 | 15 | 105810 | 1405 | 46578832 |
| Putamen haemorrhage | 11.13 | 9.21 | 6 | 105819 | 156 | 46580081 |
| Injury | 10.93 | 9.21 | 150 | 105675 | 43877 | 46536360 |
| Intraductal papillary breast neoplasm | 10.90 | 9.21 | 3 | 105822 | 10 | 46580227 |
| Blood bilirubin increased | 10.87 | 9.21 | 122 | 105703 | 34062 | 46546175 |
| Extrapyramidal disorder | 10.85 | 9.21 | 6 | 105819 | 11262 | 46568975 |
| Reticulocyte count increased | 10.74 | 9.21 | 10 | 105815 | 631 | 46579606 |
| Coma | 10.74 | 9.21 | 189 | 105636 | 58160 | 46522077 |
| Blood urea increased | 10.74 | 9.21 | 96 | 105729 | 25256 | 46554981 |
| Dyspnoea | 10.66 | 9.21 | 1329 | 104496 | 514219 | 46066018 |
| Abdominal distension | 10.60 | 9.21 | 229 | 105596 | 73122 | 46507115 |
| Hereditary angioedema | 10.58 | 9.21 | 32 | 105793 | 5484 | 46574753 |
| Hyperlipidaemia | 10.47 | 9.21 | 75 | 105750 | 18464 | 46561773 |
| Impaired work ability | 10.44 | 9.21 | 8 | 105817 | 12628 | 46567609 |
| Pupils unequal | 10.40 | 9.21 | 14 | 105811 | 1330 | 46578907 |
| Gastrointestinal haemorrhage | 10.37 | 9.21 | 239 | 105586 | 77134 | 46503103 |
| Pityriasis lichenoides et varioliformis acuta | 10.37 | 9.21 | 4 | 105821 | 46 | 46580191 |
| Haemolytic anaemia | 10.33 | 9.21 | 47 | 105778 | 9795 | 46570442 |
| Therapy non-responder | 10.33 | 9.21 | 53 | 105772 | 41099 | 46539138 |
| Reticulocyte percentage increased | 10.28 | 9.21 | 3 | 105822 | 13 | 46580224 |
| Throat tightness | 10.25 | 9.21 | 81 | 105744 | 20558 | 46559679 |
| Allergic transfusion reaction | 10.22 | 9.21 | 4 | 105821 | 48 | 46580189 |
| Dizziness postural | 10.19 | 9.21 | 35 | 105790 | 6411 | 46573826 |
| Nausea | 10.14 | 9.21 | 1738 | 104087 | 685716 | 45894521 |
| Coronary artery dissection | 10.12 | 9.21 | 10 | 105815 | 680 | 46579557 |
| Vascular resistance systemic decreased | 10.11 | 9.21 | 5 | 105820 | 108 | 46580129 |
| Myocarditis infectious | 10.10 | 9.21 | 3 | 105822 | 14 | 46580223 |
| Wrong technique in product usage process | 10.08 | 9.21 | 77 | 105748 | 54345 | 46525892 |
| Atrioventricular block complete | 10.02 | 9.21 | 39 | 105786 | 7588 | 46572649 |
| Histamine level increased | 9.93 | 9.21 | 3 | 105822 | 15 | 46580222 |
| Therapeutic hypothermia | 9.93 | 9.21 | 3 | 105822 | 15 | 46580222 |
| Ileus | 9.83 | 9.21 | 60 | 105765 | 14004 | 46566233 |
| Ovarian cancer | 9.76 | 9.21 | 32 | 105793 | 5723 | 46574514 |
| Blood magnesium decreased | 9.75 | 9.21 | 50 | 105775 | 10942 | 46569295 |
| Red blood cell count decreased | 9.74 | 9.21 | 115 | 105710 | 32508 | 46547729 |
| Colitis ischaemic | 9.63 | 9.21 | 47 | 105778 | 10085 | 46570152 |
| Blood creatine phosphokinase MB increased | 9.55 | 9.21 | 13 | 105812 | 1248 | 46578989 |
| Light chain analysis increased | 9.54 | 9.21 | 12 | 105813 | 1066 | 46579171 |
| Injection site pruritus | 9.52 | 9.21 | 52 | 105773 | 39691 | 46540546 |
| Medication error | 9.45 | 9.21 | 37 | 105788 | 30874 | 46549363 |
| Abortion spontaneous | 9.44 | 9.21 | 59 | 105766 | 43587 | 46536650 |
| Lymphocyte count decreased | 9.39 | 9.21 | 94 | 105731 | 25495 | 46554742 |
| Urticaria chronic | 9.39 | 9.21 | 8 | 105817 | 449 | 46579788 |
| Near drowning | 9.34 | 9.21 | 3 | 105822 | 19 | 46580218 |
| COVID-19 pneumonia | 9.33 | 9.21 | 22 | 105803 | 3253 | 46576984 |
| Neuroleptic malignant syndrome | 9.24 | 9.21 | 7 | 105818 | 11115 | 46569122 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic function abnormal | 141.01 | 9.90 | 319 | 74584 | 41626 | 29835949 |
| Drug ineffective | 139.37 | 9.90 | 415 | 74488 | 339972 | 29537603 |
| Drug abuse | 127.82 | 9.90 | 25 | 74878 | 82047 | 29795528 |
| Liver disorder | 92.12 | 9.90 | 219 | 74684 | 29503 | 29848072 |
| Platelet count decreased | 91.56 | 9.90 | 514 | 74389 | 105615 | 29771960 |
| Toxicity to various agents | 85.20 | 9.90 | 199 | 74704 | 176984 | 29700591 |
| Completed suicide | 84.07 | 9.90 | 75 | 74828 | 99417 | 29778158 |
| Aspartate aminotransferase increased | 81.95 | 9.90 | 345 | 74558 | 63077 | 29814498 |
| Alanine aminotransferase increased | 81.63 | 9.90 | 385 | 74518 | 73891 | 29803684 |
| White blood cell count decreased | 70.00 | 9.90 | 403 | 74500 | 83544 | 29794031 |
| Disseminated intravascular coagulation | 68.30 | 9.90 | 163 | 74740 | 22008 | 29855567 |
| Drug interaction | 57.56 | 9.90 | 280 | 74623 | 199288 | 29678287 |
| Off label use | 52.75 | 9.90 | 386 | 74517 | 248904 | 29628671 |
| General physical health deterioration | 48.16 | 9.90 | 112 | 74791 | 99832 | 29777743 |
| Neutrophil count decreased | 47.28 | 9.90 | 221 | 74682 | 42233 | 29835342 |
| Blood lactate dehydrogenase increased | 45.66 | 9.90 | 134 | 74769 | 20467 | 29857108 |
| Chronic kidney disease | 44.38 | 9.90 | 200 | 74703 | 37638 | 29839937 |
| Interstitial lung disease | 43.79 | 9.90 | 279 | 74624 | 59918 | 29817657 |
| Rheumatoid arthritis | 38.58 | 9.90 | 28 | 74875 | 41169 | 29836406 |
| Drug resistance | 36.23 | 9.90 | 4 | 74899 | 20129 | 29857446 |
| Blood alkaline phosphatase increased | 35.12 | 9.90 | 164 | 74739 | 31323 | 29846252 |
| Upper respiratory tract inflammation | 34.80 | 9.90 | 32 | 74871 | 1799 | 29875776 |
| Cerebral infarction | 32.89 | 9.90 | 142 | 74761 | 26231 | 29851344 |
| Overdose | 32.05 | 9.90 | 106 | 74797 | 84231 | 29793344 |
| Product use in unapproved indication | 32.05 | 9.90 | 87 | 74816 | 73606 | 29803969 |
| Treatment failure | 30.65 | 9.90 | 25 | 74878 | 34654 | 29842921 |
| Lymphocyte stimulation test positive | 28.51 | 9.90 | 21 | 74882 | 862 | 29876713 |
| Contraindicated product administered | 27.33 | 9.90 | 5 | 74898 | 17226 | 29860349 |
| Foetal exposure during pregnancy | 26.36 | 9.90 | 32 | 74871 | 36839 | 29840736 |
| Infusion related reaction | 24.71 | 9.90 | 180 | 74723 | 40384 | 29837191 |
| Decreased appetite | 23.88 | 9.90 | 516 | 74387 | 149394 | 29728181 |
| Psoriasis | 23.51 | 9.90 | 44 | 74859 | 42462 | 29835113 |
| Pyrexia | 23.25 | 9.90 | 928 | 73975 | 293561 | 29584014 |
| Drug intolerance | 22.40 | 9.90 | 50 | 74853 | 45241 | 29832334 |
| End stage renal disease | 22.18 | 9.90 | 54 | 74849 | 7381 | 29870194 |
| Pneumonitis | 21.04 | 9.90 | 129 | 74774 | 27325 | 29850250 |
| Blood creatine phosphokinase MB increased | 20.68 | 9.90 | 25 | 74878 | 1931 | 29875644 |
| Pneumonia bacterial | 20.67 | 9.90 | 61 | 74842 | 9342 | 29868233 |
| Haematocrit decreased | 20.32 | 9.90 | 139 | 74764 | 30560 | 29847015 |
| Blood albumin decreased | 19.88 | 9.90 | 73 | 74830 | 12519 | 29865056 |
| Erythema multiforme | 19.70 | 9.90 | 54 | 74849 | 7931 | 29869644 |
| Blood urea increased | 19.54 | 9.90 | 140 | 74763 | 31241 | 29846334 |
| Blood bilirubin increased | 19.21 | 9.90 | 157 | 74746 | 36479 | 29841096 |
| Pneumonia | 19.14 | 9.90 | 1020 | 73883 | 333286 | 29544289 |
| Hypoxia | 18.48 | 9.90 | 192 | 74711 | 47662 | 29829913 |
| Pneumonia aspiration | 18.27 | 9.90 | 159 | 74744 | 37621 | 29839954 |
| Intentional product misuse | 18.21 | 9.90 | 37 | 74866 | 34630 | 29842945 |
| Therapeutic product effect incomplete | 17.86 | 9.90 | 36 | 74867 | 33798 | 29843777 |
| Acute respiratory failure | 17.67 | 9.90 | 118 | 74785 | 25732 | 29851843 |
| Lactic acidosis | 17.54 | 9.90 | 32 | 74871 | 31181 | 29846394 |
| Intentional overdose | 17.26 | 9.90 | 50 | 74853 | 41431 | 29836144 |
| Extrapyramidal disorder | 17.18 | 9.90 | 3 | 74900 | 10690 | 29866885 |
| Ventricular tachycardia | 16.97 | 9.90 | 110 | 74793 | 23752 | 29853823 |
| Human ehrlichiosis | 16.94 | 9.90 | 9 | 74894 | 205 | 29877370 |
| PO2 increased | 16.86 | 9.90 | 13 | 74890 | 572 | 29877003 |
| Cholangitis acute | 16.28 | 9.90 | 14 | 74889 | 720 | 29876855 |
| Lower respiratory tract infection | 16.28 | 9.90 | 26 | 74877 | 26688 | 29850887 |
| Enterocolitis | 16.27 | 9.90 | 45 | 74858 | 6642 | 29870933 |
| Mast cell activation syndrome | 16.18 | 9.90 | 7 | 74896 | 99 | 29877476 |
| Rash | 16.11 | 9.90 | 609 | 74294 | 191280 | 29686295 |
| Gastrointestinal mucosal necrosis | 16.09 | 9.90 | 8 | 74895 | 158 | 29877417 |
| Wound secretion | 15.84 | 9.90 | 25 | 74878 | 2483 | 29875092 |
| Infective pulmonary exacerbation of cystic fibrosis | 15.52 | 9.90 | 52 | 74851 | 8520 | 29869055 |
| Hepatocellular injury | 15.33 | 9.90 | 25 | 74878 | 25446 | 29852129 |
| Constipation | 15.28 | 9.90 | 380 | 74523 | 112526 | 29765049 |
| Torsade de pointes | 15.20 | 9.90 | 46 | 74857 | 7144 | 29870431 |
| Glossectomy | 14.98 | 9.90 | 3 | 74900 | 0 | 29877575 |
| Sepsis | 14.61 | 9.90 | 474 | 74429 | 145921 | 29731654 |
| CADASIL | 14.39 | 9.90 | 6 | 74897 | 77 | 29877498 |
| Ultrasound skull abnormal | 14.39 | 9.90 | 6 | 74897 | 77 | 29877498 |
| Intentional product use issue | 14.39 | 9.90 | 45 | 74858 | 36395 | 29841180 |
| Magnetic resonance imaging spinal abnormal | 14.12 | 9.90 | 6 | 74897 | 81 | 29877494 |
| Renal impairment | 14.10 | 9.90 | 292 | 74611 | 83892 | 29793683 |
| Respiratory failure | 14.00 | 9.90 | 340 | 74563 | 100302 | 29777273 |
| Visual evoked potentials abnormal | 13.80 | 9.90 | 6 | 74897 | 86 | 29877489 |
| Convulsions local | 13.78 | 9.90 | 4 | 74899 | 15 | 29877560 |
| Gastrooesophageal reflux disease | 13.70 | 9.90 | 132 | 74771 | 32123 | 29845452 |
| Convulsive threshold lowered | 13.62 | 9.90 | 11 | 74892 | 518 | 29877057 |
| Cytokine release syndrome | 13.57 | 9.90 | 55 | 74848 | 9878 | 29867697 |
| Joint swelling | 13.41 | 9.90 | 66 | 74837 | 46880 | 29830695 |
| Physical examination abnormal | 13.20 | 9.90 | 6 | 74897 | 96 | 29877479 |
| Psychotic disorder | 13.05 | 9.90 | 21 | 74882 | 21494 | 29856081 |
| Anal erosion | 13.03 | 9.90 | 4 | 74899 | 19 | 29877556 |
| Protein total decreased | 13.02 | 9.90 | 34 | 74869 | 4851 | 29872724 |
| Febrile neutropenia | 12.96 | 9.90 | 354 | 74549 | 106339 | 29771236 |
| Urticaria | 12.90 | 9.90 | 200 | 74703 | 54406 | 29823169 |
| Pneumonia staphylococcal | 12.89 | 9.90 | 25 | 74878 | 2926 | 29874649 |
| Central nervous system inflammation | 12.88 | 9.90 | 6 | 74897 | 102 | 29877473 |
| Catheter site haemorrhage | 12.83 | 9.90 | 21 | 74882 | 2151 | 29875424 |
| Burkholderia test positive | 12.80 | 9.90 | 10 | 74893 | 449 | 29877126 |
| Depressed level of consciousness | 12.75 | 9.90 | 149 | 74754 | 38073 | 29839502 |
| Double stranded DNULL antibody positive | 12.72 | 9.90 | 6 | 74897 | 105 | 29877470 |
| Death | 12.69 | 9.90 | 748 | 74155 | 356535 | 29521040 |
| Rash maculo-papular | 12.62 | 9.90 | 28 | 74875 | 25390 | 29852185 |
| Ventricular flutter | 12.45 | 9.90 | 5 | 74898 | 58 | 29877517 |
| Blood pressure decreased | 12.13 | 9.90 | 175 | 74728 | 46900 | 29830675 |
| Eczema asteatotic | 12.10 | 9.90 | 7 | 74896 | 189 | 29877386 |
| Hypertensive crisis | 12.08 | 9.90 | 3 | 74900 | 8354 | 29869221 |
| Post procedural haematoma | 12.04 | 9.90 | 17 | 74886 | 1530 | 29876045 |
| Sputum retention | 11.99 | 9.90 | 10 | 74893 | 493 | 29877082 |
| Cerebral microangiopathy | 11.97 | 9.90 | 7 | 74896 | 193 | 29877382 |
| Conduction disorder | 11.71 | 9.90 | 19 | 74884 | 1932 | 29875643 |
| Saccadic eye movement | 11.52 | 9.90 | 6 | 74897 | 131 | 29877444 |
| Ejaculation delayed | 11.44 | 9.90 | 7 | 74896 | 210 | 29877365 |
| Jaundice hepatocellular | 11.42 | 9.90 | 5 | 74898 | 73 | 29877502 |
| Haemorrhagic diathesis | 11.30 | 9.90 | 23 | 74880 | 2788 | 29874787 |
| Tunnel vision | 11.29 | 9.90 | 9 | 74894 | 416 | 29877159 |
| White blood cell count increased | 11.24 | 9.90 | 150 | 74753 | 39523 | 29838052 |
| Hiccups | 11.15 | 9.90 | 50 | 74853 | 9384 | 29868191 |
| Polyneuropathy | 11.11 | 9.90 | 8 | 74895 | 11815 | 29865760 |
| Musculoskeletal stiffness | 11.10 | 9.90 | 49 | 74854 | 35832 | 29841743 |
| Hepatitis fulminant | 11.10 | 9.90 | 28 | 74875 | 3913 | 29873662 |
| Hyperuricaemia | 10.95 | 9.90 | 42 | 74861 | 7352 | 29870223 |
| Stevens-Johnson syndrome | 10.74 | 9.90 | 78 | 74825 | 17478 | 29860097 |
| Blood pH decreased | 10.71 | 9.90 | 20 | 74883 | 2275 | 29875300 |
| Inappropriate schedule of product administration | 10.69 | 9.90 | 57 | 74846 | 39671 | 29837904 |
| Pancreatic enlargement | 10.62 | 9.90 | 5 | 74898 | 87 | 29877488 |
| Cholestasis | 10.43 | 9.90 | 30 | 74873 | 24920 | 29852655 |
| Coma | 10.36 | 9.90 | 59 | 74844 | 40390 | 29837185 |
| Paraneoplastic syndrome | 10.33 | 9.90 | 9 | 74894 | 471 | 29877104 |
| BRASH syndrome | 10.31 | 9.90 | 4 | 74899 | 42 | 29877533 |
| Inappropriate antidiuretic hormone secretion | 10.27 | 9.90 | 56 | 74847 | 11366 | 29866209 |
| Staphylococcal sepsis | 10.26 | 9.90 | 49 | 74854 | 9442 | 29868133 |
| Oral pruritus | 10.19 | 9.90 | 7 | 74896 | 257 | 29877318 |
| Arthropathy | 10.15 | 9.90 | 23 | 74880 | 20704 | 29856871 |
| Drug dependence | 10.13 | 9.90 | 24 | 74879 | 21271 | 29856304 |
| Urine osmolarity decreased | 10.07 | 9.90 | 4 | 74899 | 45 | 29877530 |
| Progressive multifocal leukoencephalopathy | 10.01 | 9.90 | 5 | 74898 | 9008 | 29868567 |
| Aortic rupture | 9.95 | 9.90 | 5 | 74898 | 101 | 29877474 |
| Psoriatic arthropathy | 9.93 | 9.90 | 15 | 74888 | 15746 | 29861829 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BA03 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
| ATC | A02BA53 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
| FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
| FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
| CHEBI has role | CHEBI:37961 | h2-receptor blockers |
| CHEBI has role | CHEBI:49201 | anti-ulcer agents |
| CHEBI has role | CHEBI:50183 | cytochrome p450 inhibitor |
| MeSH PA | D000897 | Anti-Ulcer Agents |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D018494 | Histamine Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006635 | Histamine H2 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Heartburn | indication | 16331000 | |
| Erosive esophagitis | indication | 40719004 | |
| Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
| Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
| Peptic reflux disease | indication | 57643001 | |
| Indigestion | indication | 162031009 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Gastric ulcer | indication | 397825006 | DOID:10808 |
| Dyspepsia Prevention | indication | ||
| Maintenance of Healing Duodenal Ulcer | indication | ||
| Heartburn Prevention | indication | ||
| Upper gastrointestinal hemorrhage | off-label use | 37372002 | |
| Prevention of Stress Ulcer | off-label use | ||
| Constipation | contraindication | 14760008 | DOID:2089 |
| Sarcoidosis | contraindication | 31541009 | DOID:11335 |
| Dehydration | contraindication | 34095006 | |
| Diarrhea | contraindication | 62315008 | |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Kidney stone | contraindication | 95570007 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Osteolysis | contraindication | 203522001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.84 | acidic |
| pKa2 | 12.0 | acidic |
| pKa3 | 6.97 | Basic |
| pKa4 | 6.37 | Basic |
| pKa5 | 2.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 7.93 | WOMBAT-PK | CHEMBL | |||
| Heat shock protein HSP 90-alpha | Cytosolic other | IC50 | 5.30 | WOMBAT-PK | |||||
| Solute carrier family 22 member 3 | Transporter | IC50 | 4.97 | CHEMBL | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 4.44 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.44 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 6.12 | CHEMBL | |||||
| Histamine H2 receptor | GPCR | Kd | 7 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017970 | VUID |
| N0000146320 | NUI |
| D00318 | KEGG_DRUG |
| 4017970 | VANDF |
| C0015620 | UMLSCUI |
| CHEBI:4975 | CHEBI |
| FO9 | PDB_CHEM_ID |
| CHEMBL902 | ChEMBL_ID |
| DB00927 | DRUGBANK_ID |
| 3325 | PUBCHEM_CID |
| D015738 | MESH_DESCRIPTOR_UI |
| 7074 | IUPHAR_LIGAND_ID |
| 5217 | INN_ID |
| 5QZO15J2Z8 | UNII |
| 4278 | RXNORM |
| 41331 | MMSL |
| 4713 | MMSL |
| d00141 | MMSL |
| 003417 | NDDF |
| 387211002 | SNOMEDCT_US |
| 39128000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Famotidine | HUMAN OTC DRUG LABEL | 1 | 0093-2748 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
| Good Sense Dual Action Complete | HUMAN OTC DRUG LABEL | 3 | 0113-0032 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
| good sense acid reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
| Good Sense Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
| basic care acid reducer | HUMAN OTC DRUG LABEL | 1 | 0113-7141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
| Basic Care famotidine | HUMAN OTC DRUG LABEL | 1 | 0113-7194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 14 sections |
| basic care dual action complete | HUMAN OTC DRUG LABEL | 3 | 0113-7321 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5728 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 25 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5729 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 25 sections |
| Pepcid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4420 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 25 sections |
| Pepcid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4440 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 25 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-5197 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
| Acid ControllerOriginal Strength | HUMAN OTC DRUG LABEL | 1 | 0363-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
| Acid Controller Completedual action | HUMAN OTC DRUG LABEL | 3 | 0363-0321 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
| Acid Reducer Complete | HUMAN OTC DRUG LABEL | 3 | 0363-0511 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
| Acid Controller | HUMAN OTC DRUG LABEL | 1 | 0363-0701 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
| Acid Reducer Complete | HUMAN OTC DRUG LABEL | 3 | 0363-0713 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
| Famotidine | Human OTC Drug Label | 1 | 0363-4400 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 16 sections |
| Famotidine | Human OTC Drug Label | 1 | 0363-5300 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 16 sections |
| Rugby Famotidine | HUMAN OTC DRUG LABEL | 1 | 0536-1298 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
| DUO Fusion | HUMAN OTC DRUG LABEL | 3 | 0597-0315 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 13 sections |
| DUO Fusion | HUMAN OTC DRUG LABEL | 3 | 0597-0320 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 13 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-4582 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 20 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8301 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 20 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6021 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6022 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6023 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
| heartburn relieforiginal strength | HUMAN OTC DRUG LABEL | 1 | 0904-5529 | TABLET | 10 mg | ORAL | ANDA | 15 sections |
| Major Heartburn ReliefMaximum Strength | HUMAN OTC DRUG LABEL | 1 | 0904-5780 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
| Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-481 | TABLET | 20 mg | ORAL | ANDA | 21 sections |